Our #1 AI Stock Pick is on a steep discount - 29$ instead of 99$! Click here to access exclusive investment research and ad free browsing! Our #1 AI Stock Pick is on a steep discount - 29$ instead of 99$! Click here to access exclusive research! Scout Investments, an affiliate of Carillon Tower Advisers, an investment management company, released its “Carillon Scout Small Cap Fund” third quarter 2022 investor letter. You can download a copy of the same here. The fund underperformed in the quarter relative to its Russell 2000 Growth Index benchmark. Macroeconomic headwinds affected the performance of the fund in the quarter. As per the letter, investors prefer growth stocks to value stocks, as small-cap growth stocks outperformed small-cap value stocks during the quarter. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022. Carillon Tower Advisers highlighted stocks like Coherus BioSciences, Inc. (NASDAQ:CHRS) in its Q3 2022 investor letter. Headquartered in Redwood City, California, Coherus BioSciences, Inc. (NASDAQ:CHRS) is a biopharmaceutical company. On December 30, 2022, Coherus BioSciences, Inc. (NASDAQ:CHRS) stock closed at $7.92 per share. One-month return of Coherus BioSciences, Inc. (NASDAQ:CHRS) was 17.51%, and its shares lost 51.74% of their value over the last 52 weeks. Coherus BioSciences, Inc. (NASDAQ:CHRS) has a market capitalization of $616.001 million. Carillon Tower Advisers made the following comment about Coherus BioSciences, Inc. (NASDAQ:CHRS) in its Q3 2022 investor letter: “Coherus BioSciences, Inc. (NASDAQ:CHRS) is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of immunotherapies to treat cancer. The company’s stock reacted positively to the approval of its biosimilar CimerliTM to treat retinal disease.” Copyright: dolgachov / 123RF Stock Photo Coherus BioSciences, Inc. (NASDAQ:CHRS) is not on our 30 Most Popular Stocks Among Hedge Funds list. As per our database, 20 hedge fund portfolios held Coherus BioSciences, Inc. (NASDAQ:CHRS) at the end of the third quarter, which was 23 in the previous quarter. We discussed Coherus BioSciences, Inc. (NASDAQ:CHRS) in another article and shared Carillon Tower Advisers’ views on the company. In addition, please check out our hedge fund investor letters Q3 2022 page for more investor letters from hedge funds and other leading investors. Suggested Articles: Disclosure: None. This article is originally published at Insider Monkey. NASDAQ:CHRSYahoo FinanceDaily Newsletter Returns since its inception in May 2014 (through May 20, 2024) Warren Buffett Berkshire Hathaway $293,447,417,000 David Einhorn Greenlight Capital $1,491,303,000 George Soros Soros Fund Management $5,416,602,000 Jim Simons Renaissance Technologies $77,426,184,000 Leon Cooperman Omega Advisors $1,886,381,000 Carl Icahn Icahn Capital LP $22,521,664,000 Steve Cohen Point72 Asset Management $22,767,998,000 John Paulson Paulson & Co $3,510,256,000 David Tepper Appaloosa Management LP $4,198,712,000 Paul Tudor Jones Tudor Investment Corp $6,160,740,000                                                            Get our editor’s daily picks straight in your inbox! 